Pharmaceuticals, Biotech and Life Sciences - Emerging and High Growth Companies

When it comes to the development of new medicines and treatments for the healthcare sector, in many cases, the most innovative work is being done by emerging and high-growth pharmaceutical companies. The increase and popularity of biologic medications, for instance, has given small-to-mid-sized pharmaceutical firms in Canada an ability to grow or expand.

For Canada’s emerging and high-growth pharmaceutical companies to succeed in this global industry with increasing competition, they must have continuous access to growth capital, strategies for intellectual property protection and a deep understanding of the regulatory environment. Delays caused by dealing with the complexity of regulatory bodies could allow a competitor to take a similar product to market first.

Osler has a long-standing commitment to supporting emerging and high-growth firms wherever they are in their growth trajectory. With our extensive work at every stage of a company’s life cycle, we are prepared to assist in securing capital, pilot program launches, tax issues, M&A deals or understanding the regulatory complexities of the sector. Our Pharmaceutical, Biotech and Life Sciences Group is also strategically situated in major Canadian research and development hubs in Toronto, Ottawa and Montréal. Thanks to our extensive business network, we can also help clients identify new opportunities.

As this space continues to evolve, the need for innovative high-growth operations will only increase. It’s important to work with a team that understands what you’re going through and can help you succeed.

Recent experience

CDL Rapid Screening Consortium

CDL Rapid Screening Consortium in the establishment of a rapid screening system and operational implementation strategy for COVID-19 to benefit the public in Canada and the rest of the world.

Learn more about our work with CDL Rapid Screening Consortium
Close up photo of female scientist holding a laboratory pipette and a blood sample tube for covid-19 in laboratory.

Fairhaven Pharmaceuticals

Fairhaven Pharmaceuticals in its acquisition by Liminal BioSciences. The acquisition includes Fairhaven’s preclinical research program of small molecule antagonists. The acquisition continues Liminal’s strategic expansion to create a diverse portfolio of early stage R&D programs that complement its existing research.

Learn more about our work with Fairhaven Pharmaceuticals
A pipette filling vaccine bottles

Deep Genomics

Deep Genomics in its $180 million Series C financing round, led by SoftBank Vision Fund 2. The capital raised will help expand the AI Workbench and scale its pipeline to 30 programs. Deep Genomics uses AI and machine learning to program and prioritize transformational RNA therapeutics for genetic diseases.

Learn more about our work with Deep Genomics
Modern Artificial Intelligence interface

Coastal Genomics

Coastal Genomics in its $17.9 million acquisition by Yourgene Health. The acquisition will allow Yourgene to extend its intellectual property profile in the DNA sample preparation sector. Coastal Genomics is a DNA sample preparation company and was named an ‘Emerging Rocket’ in the life sciences category by Rocket Builders.

Learn more about our work with Coastal Genomics
Scientist holding a test tube while working with a microscope
Find more deals and cases